December 23, 2025
Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment
Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1
Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy
Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea
Patient Dies from Thrombotic Stroke in Pfizer’s Hympavzi Hemophilia Trial After Minor Surgery
Pfizer; Hympavzi; marstacimab; hemophilia; thrombotic stroke; patient death; clinical trial
Gilead’s $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals
Gilead; Assembly Biosciences; herpes; HSV; ABI-1179; ABI-5366; FDA; Boehringer; Roche
Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline
Aktis Oncology; IPO; Eli Lilly; radiopharmaceuticals; AKY-1189; AKTS
Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma
Shionogi; Tanabe Pharma; Radicava; ALS; acquisition; $2.5B; rare disease
FDA Approves Novo Nordisk’s Wegovy Pill as First Oral GLP-1 for Weight Management
Novo Nordisk; Wegovy pill; FDA approval; obesity treatment; oral semaglutide
Spotlight On: Five Key FDA Approvals of 2025
FDA approvals; 2025; orphan drugs; novel therapies; rare diseases
Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients
Brainomix; AI; stroke trial; ARG-007; neuroprotective; Argenica Therapeutics; Brainomix 360 Stroke